Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)

G Kong; M Thompson; M Collins; A Herschtal; MS Hofman; V Johnston; P Eu; M Michael; RJ Hicks

Journal article

Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)

G Kong, M Thompson, M Collins, A Herschtal, MS Hofman, V Johnston, P Eu, M Michael, RJ Hicks

European Journal of Nuclear Medicine and Molecular Imaging | Published : 2014

DOI: 10.1007/s00259-014-2788-5

Download PDF

Abstract

Purpose: To review the response and outcomes of 177Lu-DOTA-octreotate chemoradionuclide therapy (LuTate PRCRT) in patients with neuroendocrine tumour (NET) expressing high levels of somatostatin receptors with uncontrolled symptoms or disease progression.Methods: A total of 68 patients (39 men; 17 – 76 years of age) who had completed an induction course of at least three cycles of LuTate PRCRT between January 2006 and June 2010 were reviewed. Ten patients were treated for uncontrolled symptoms and 58 had disease progression despite conventional treatment. The majority had four induction LuTate cycles (median treatment duration 5 months and cumulative activity 31 GBq), and 63 patients had con..

View full abstract

University of Melbourne Researchers

Grace Kong Author

Marnie Downes Author

Michael Hofman Author

Michael Michael Author

Grants

Funding Acknowledgements

Professor Hicks was the recipient of a translational research grant from the Victorian Cancer Agency, which supported establishment of a prospective database of all patients referred for PRRT. The authors would like to thank the patients, their families and our referring doctors for their trust in and support of our programme, the Unicorn Foundation for its advocacy for NET patients and our NET nurses for their diligence and care of our patients.